Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016 Oct 19;6(10):e012488.
doi: 10.1136/bmjopen-2016-012488.

Safety and immunogenicity of a new 13-valent pneumococcal conjugate vaccine versus a licensed 7-valent pneumococcal conjugate vaccine: a study protocol of a randomised non-inferiority trial in China

Jing Jing Chen  1   2 , Lin Yuan  2 , Zhen Huang  2 , Nian Min Shi  3 , Yu Liang Zhao  4 , Sheng Li Xia  5 , Guo Hua Li  6 , Rong Cheng Li  7 , Yan Ping Li  7 , Shu Yuan Yang  2 , Jie Lai Xia  1
Affiliations
Clinical Trial

Safety and immunogenicity of a new 13-valent pneumococcal conjugate vaccine versus a licensed 7-valent pneumococcal conjugate vaccine: a study protocol of a randomised non-inferiority trial in China

Jing Jing Chen et al. BMJ Open. .

Abstract

Introduction: The invasive pneumococcal diseases (IPDs) caused by Streptococcus pneumoniae pose an enormous threat to children under 5 years of age. However, routine use of pneumococcal conjugate vaccines could aid in reducing the incidence of IPDs. The purpose of this clinical trial is to assess the non-inferiority of the investigational 13-valent pneumococcal conjugate vaccine (PCV13) to the currently licensed 7-valent pneumococcal conjugate vaccine (PCV7).

Methods and analysis: 1040 infants will receive a three-dose series of either PCV13 or PCV7 at ages 3, 4 and 5 months, respectively, and a booster dose at 12-15 months. Primary end points are the percentage of participants reaching a serotype-specific IgG concentration of ≥0.35 µg/mL and the IgG antibody geometric mean concentrations (GMCs) measured 30 days after the primary immunisation. Secondary end points include the percentage of vaccine recipients reaching a serotype-specific IgG concentration threshold of 1.0 µg/mL, the percentage of participants reaching the pneumococcal opsonophagocytic assay (OPA) titre threshold of 1:8, and the geometric mean titres (GMTs) of OPA measured 30 days after primary and booster doses. The number of standard IgG responders and IgG GMCs measured 30 days after the booster immunisation will also be determined. To evaluate differences between two groups, the sequential testing of the non-inferiority of PCV13 for the seven common serotypes and its effectiveness in treating the six additional serotypes will be performed.

Ethics and dissemination: Ethics approvals have been granted by the Ethics Committees at the three provinces involved in this study: Shanxi, Henan and Hebei. The trial will be reported in accordance with the CONSORT guidance.

Trial registration number: NCT02736240.

Keywords: Non-inferiority; Pneumococcal conjugate vaccine; Sequential test.

PubMed Disclaimer

Conflict of interest statement

We have read and understood BMJ policy on declaration of interests and declare the following interests: This trial is sponsored by Walvax Biotechnology Co. Walvax, as the sponsor, is responsible for organising and managing the study to support the prelicensing evaluation of the investigational PCV13. The new PCV13 was researched and developed by Walvax and manufactured by an affiliate of Walvax. JJC, LY, ZH and SYY work at Walvax and belong to the clinical research team of PCV13.

Figures

Figure 1
Figure 1
The study flow diagram.
Figure 2
Figure 2
The sequential test flow chart. GMC, geometric mean concentrations; PCV13, 13-valent pneumococcal conjugate vaccine; PCV7, 7-valent pneumococcal conjugate vaccine.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. WHO. Pneumococcal conjugate vaccine for childhood immunization—WHO position paper. Wkly Epidemiol Rec 2007;82:93–104. - PubMed
    1. O'Brien KL, Wolfson LJ, Watt JP et al. . Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009;374:893–902. 10.1016/S0140-6736(09)61204-6 - DOI - PubMed
    1. WHO. Pneumonia WHO Fact sheet N°331. http://www.who.int/mediacentre/factsheets/fs331/en/ (accessed 25 Nov 2015).
    1. American Academy of Pediatrics Committee on Infectious D. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23). Pediatrics 2010;126:186–90. 10.1542/peds.2010-1280 - DOI - PubMed
    1. Black S. The volatile nature of pneumococcal serotype epidemiology: potential for misinterpretation. Pediatr Infect Dis J 2010;29:301–3. 10.1097/INF.0b013e3181c391fb - DOI - PubMed

Publication types

MeSH terms

Substances

Associated data